Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells

Journal of Pineal Research

Volumn 54, Issue 4, 2013, Pages 373-380

  Alvarez García, Virginia ^a   González, Alicia ^a   Alonso González, Carolina ^a   Martínez Campa, Carlos ^a   Cos, Samuel ^a,b  

^a UNIVERSITY OF CANTABRIA   (Spain)

^b UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Breast cancer; Endothelial cells; MCF 7 cells; Melatonin; Pineal gland; Vascular endothelial growth factor

Indexed keywords

ESTROGEN; MELATONIN; MESSENGER RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL COUNT; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UMBILICAL VEIN ENDOTHELIAL CELL;

BREAST CANCER; ENDOTHELIAL CELLS; MCF-7 CELLS; MELATONIN; PINEAL GLAND; VASCULAR ENDOTHELIAL GROWTH FACTOR;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; FEMALE; HUMANS; MCF-7 CELLS; MELATONIN; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84879464467     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12007     Document Type: Article

References (47)

1. BERGERS G, BENJAMIN LE. Tumorigenesis and the antiangiogenic switch. Nat Rev Cancer 2003; 3:401-410.
2. BARESCHINO MA, SCHETTINO C, COLANTUONI G et al. The role of antiangiogenic agents in the treatment of breast cancer. Curr Med Chem 2011; 18:5022-5032.
3. COOK KM, FIGG WD. Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 2010; 60:222-243.
4. SENGER DR, VAN DE WATER L, BROWN LF et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12:303-324.
5. HANAHAN D, CHRISTOFORI G, NAIK P, ARBEIT J. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects of preclinical therapeutic models. Eur J Cancer 1996; 32A:2386-2393.
6. SALVEN P, MÄNPÄÄH, ORPANA A et al. Serum endothelial growth factor is often evaluated in disseminated cancer. Clin Cancer Res 1997; 3:647-651.
7. HILL SM, BLASK DE. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res 1988; 48:6121-6126.
8. COS S, SÁNCHEZ-BARCELÓEJ. Melatonin and mammary pathological growth. Front Neuroendocrinol 2000; 21:133-170.
9. BLASK DE, SAUER LA, DAUCHY RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadianbased cancer therapy. Curr Topics Med Chem 2002; 2:113-132.
10. SÁNCHEZ-BARCELÓEJ, COS S, FERNÁNDEZ R et al. Melatonin and mammary cancer: a short review. Endocr Relat Cancer 2003; 10:153-159.
11. COS S, GONZÁLEZ A, MARTÍNEZ-CAMPA C et al. Estrogensignaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev 2006; 30:118-128.
12. COS S, GONZÁLEZ A, MARTÍNEZ-CAMPA C et al. Melatonin as a selective estrogen enzyme modulator. Curr Cancer Drug Tar 2008; 8:691-702.
13. GONZÁLEZ A, COS S, MARTINEZ-CAMPA C et al. Selective estrogen enzime modulator (SEEM) actions of melatonin in human breast cancer cells. J Pineal Res 2008; 45:86-92.
14. COS S, MARTÍNEZ-CAMPA C, MEDIAVILLA MD, ALONSO-GONZÁLEZ C, SÁNCHEZ-BARCELÓEJ. Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 2005; 38:136-142.
15. COS S, GONZÁLEZ A, GÜEZMES A et al. Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 2006; 118:274-278.
16. MENG L, ZHOU J, SASANO H et al. Tumor necrosis factor α and interleukin 11 secreted by malignant breast epitelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ: mechasnism of desmoplastic reaction. Cancer Res 2001; 61:2250-2255.
17. BULUN SE, CHEN D, LU M et al. Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol 2007; 106:81-96.
18. GONZÁLEZ A, ALVAREZ-GARCÍA V, MARTÍNEZ-CAMPA C et al. Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res 2012; 52:12-20.
19. ALVAREZ-GARCÍA V, GONZÁLEZ A, ALONSO-GONZÁLEZ C et al. Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 2012; 52:282-290.
20. HARADA N, SASANO H, MURAKAMI H et al. Localized expression of aromatase in human vascular tissues. Circ Res 1999; 84:1285-1291.
21. MUKHERJEE TK, DINH H, CHAUDHURI G et al. Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Nat Acad Sci USA 2002; 6:4055-4060.
22. COS S, GONZÁLEZ A, ALVAREZ-GARCÍA V et al. Melatonin and breast cancer: selective estrogen enzyme modulator actions. In: Advances in Cancer Drug Targets, Atta-ur-Rahman ed., Bentham Science Publishers, Sharjah, U.A.E, 2012; 1:in press.
23. GU Q, WANG D, WANG X et al. Basic fibroblast growth factor inhibits radiation-induced apoptosis of HUVECs. 1. The P13k/AKT pathway and induction of phosphorylation of BAD. Radiat Res 2004; 161:692-702.
24. GINGIS-VELITSKI S, ZETSER A, FLUGELMAN MY et al. Heparanase induces endothelial cell migration via protein kinase B/Akt activation. J Biol Chem 2004; 279:23536-23541.
25. GERBER HP, MCMURTREY A, KOWALSKI J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation.. J Biol Chem 1998; 273:30336-30343.
26. PASQUALINI JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004; 1654:123-143.
27. BULUN SE, LIN Z, IMIR G et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev 2005; 57:359-383.
28. PASQUALINI JR, CHETRITE GS. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol 2005; 93:221-236.
29. SUZUKI T, MIKI Y, NAKAMURA Y et al. Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer 2005; 12:701-720.
30. PUROHIT A, NEWMAN SP, REED MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002; 4:65-69.
31. GUERRERO J, TOBAR N, CÁCERES M et al. Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-β1 and TNF-α. Breast Cancer Res Treat 2010; 119:497-508.
32. BRODIE AM, NJAR VC. Aromatase inhibitors and their application in breast cancer treatment. Steroids 2000; 65:171-179.
33. COS S, SÁNCHEZ-BARCELÓ EJ. Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol 2000; 15:637-647.
34. SÁNCHEZ-BARCELÓ EJ, COS S, MEDIAVILLA MD et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38:217-222.
35. MARTÍNEZ-CAMPA C, GONZÁLEZ A, MEDIAVILLA MD et al. Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cáncer cells. Br J Cancer 2009; 101:1613-1619
36. MOLIS TM, SPRIGGS LL, HILL SM. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol 1994; 8:1681-1690.
37. HILL SM, SPRIGGS LL, SIMON MA et al. The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett 1992; 64:249-256.
38. DEL RÍO B, GARCÍA-PEDRERO JM, MARTÍNEZ-CAMPA C, ZUAZUA P, LAZO PS, RAMOS S. Melatonin: an endogenous specific inhibitor of estrogen receptor α via calmodulin. J Biol Chem 2004; 279:38294-38302.
39. CRESPO D, FERNÁNDEZ-VIADERO C, VERDUGA R et al. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res 1994; 16:215-222.
40. COS S, FERNÁNDEZ R. Melatonin effects on intercellular junctional communication in MCF-7 human breast cancer cells. J Pineal Res 2000; 29:166-171.
41. COS S, FERNÁNDEZ R, GÜÉZMES A et al. Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res 1998; 58:4383-4390.
42. LIANG Y, HYDER SM. Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology 2005; 146:3632-3641.
43. CUI P, LUO Z, ZHANG H et al. Effect and mechanism of melatonin's action on the proliferation of human umbilical vein endothelial cells. J Pineal Res 2006; 41:358-362.
44. 2 in cultured cancer cells. J Pineal Res 2008; 44:121-126.
45. CUI P, YU M, PENG X et al. Melatonin prevents human pancreatic carcinoma cell PANC-1-induced human vein endothelial cell proliferation and migration by inhibiting vascular endothelial growth factor expression. J Pineal Res 2012; 52:236-243.
46. PARK SY, JANG WJ, YI EY et al. Melatonin suppresses tumor angiogenesis by inhibiting HIF-1α stabilization under hypoxia. J Pineal Res 2010; 48:178-184.
47. KAUR C, SIVAKUMAR V, LU J et al. Increased vascular permeability and nitric oxide production in response to hypoxia in the pineal gland. J Pineal Res 2007; 42:338-349.